Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.6M | $15.4M | $60.4M | $73.4M | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | $107M |
| Revenue growth | — | -68.4% | 292.4% | 21.6% | -2.1% | -23.0% | -7.2% | 11.8% | 12.1% | 66.9% |
| Operating income | -$180M | -$260M | -$239M | -$252M | -$298M | -$258M | -$92.0M | -$56.0M | -$46.9M | -$3.60M |
| Operating margin | -371.0% | -1690.6% | -395.5% | -343.1% | -414.2% | -466.1% | -179.1% | -97.6% | -72.9% | -3.4% |
| Net income | -$191M | -$285M | -$216M | -$236M | -$278M | -$199M | $872M | -$55.2M | -$56.4M | $106M |
| Net margin | -391.9% | -1855.0% | -357.0% | -322.1% | -386.9% | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
| EPS (diluted) | -$4.26 | -$5.45 | -$3.99 | -$4.25 | -$4.46 | -$2.87 | $11.85 | -$1.00 | -$1.15 | $2.06 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$99.0M | -$201M | -$113M | -$238M | -$250M | -$208M | -$187M | -$27.0M | -$11.5M | $239M |
| Capital expenditures | $2.13M | $2.41M | $7.24M | $3.18M | $6.62M | $3.41M | $572K | $2.49M | $332K | $42.0K |
| Free cash flow | -$101M | -$203M | -$120M | -$241M | -$257M | -$211M | -$188M | -$29.5M | -$11.9M | $238M |
| Share buybacks | — | — | — | — | — | — | $129M | $197M | $445K | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $345M | $89.0M | $378M | $58.1M | $81.5M | $90.0M | $298M | $39.5M | $37.8M | $168M |
| Total assets | $639M | $441M | $560M | $409M | $469M | $375M | $607M | $382M | $354M | $486M |
| Long-term debt | — | $224M | $454M | $455M | $619M | $616M | — | $0.00 | — | — |
| Shareholders' equity | $350M | $115M | -$51.6M | -$224M | -$304M | -$339M | $442M | $213M | $176M | $297M |
| Retained earnings | -$512M | -$798M | -$1.01B | -$1.25B | -$1.53B | -$1.73B | -$854M | -$909M | -$966M | -$860M |
| Shares (wtd avg diluted) | 52.8M | 52.4M | 54.0M | 55.6M | 62.3M | 69.5M | 73.6M | 55.3M | 48.8M | 51.5M |
Every figure is extracted from Theravance Biopharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.